ComplianceOnline

Risk Information in Prescription Drug & Medical Device Ads, Promotional Labeling – What the FDA Expects

  • By: Staff Editor
  • Date: November 17, 2011
Webinar All Access Pass Subscription Abstract:

The FDA has issued a draft guidance document on how manufacturers should present risk information in promotional material and ads for prescription drugs and medical devices. It describes the factors that the agency takes into consideration when evaluating ads and promotional labeling for prescription drugs and medical devices.

This article gives an overview and summary of the recommendations included in the FDA guidance.

Bookmark and Share

Trending Compliance Trainings

You have a BI or Sterility Failure - Now What?
By - Gerry O Dell
On Demand Access Anytime
QA Agreements for ISO 13485:2019 and other Regulatory Compliance
By - Betty Lane
On Demand Access Anytime
Classifying Medical Devices - US and EU
By - Charles H Paul
On Demand Access Anytime
User / Human Factors Engineering Under IEC 62366-1, -2
By - John E Lincoln
On Demand Access Anytime
How to Interpret Probability Plots
By - Jerry Phillips
On Demand Access Anytime
Medical Device Software Verification and Validation
By - Nancy Knettell
On Demand Access Anytime
Overview of Medical Device Regulation in Europe
By - Rebecca Kemble
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading